Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company focused on complement-based therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Syfovre safety check: Real-World study tracks eye drug in 300 patients Results expected Jun 2027 (estimated)
- New drug combo aims to halt blindness from 'Dry' macular degeneration Results expected Jun 2027 (estimated)
- New drug shows promise for controlling rare kidney disorders Results expected Jul 2027 (estimated)
-
New hope for FSGS: experimental drug APL2 enters Late-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called APL2 for people with a kidney disease called FSGS. The goal is to see if APL2 can reduce protein in the urine, a sign of kidney damage. The trial has two parts: first, adults will receive APL2 openly; then, both adults and adolescents …
Phase 2/3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug pegcetacoplan tested in teens with rare blood disorder
Disease control Recruiting nowThis study tests a drug called pegcetacoplan in 12 to 17-year-olds with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The drug aims to control the disease by blocking part of the immune system. The trial will check safety, how the…
Phase 2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to halt blindness from 'Dry' macular degeneration
Disease control Recruiting nowThis Phase 2 trial tests whether adding APL-3007 to the existing drug Syfovre (pegcetacoplan) can better slow geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 240 adults aged 60 and older with the condition will receive e…
Phase 2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC